Policymakers should consider disbanding the 340B program “given its negative reverberations for patients and markets,” a student and a professor at the Stanford University School of Medicine wrote in a commentary in the latest edition of the New England Journal of Medicine.
Groups that represent hospitals enrolled in 340B criticized the article (subscription required). They said abolishing the drug discount program would harm rather than help patients, communities, and health care at large.
Policymakers should consider disbanding the 340B program “given its negative reverberations for patients and markets,” a student and a professor at the Stanford University School of Medicine wrote in a commentary in the latest edition of the New England Journal of Medicine.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
